In high-income countries, causes of death in people living with HIV (PLHIV) have changed. Three French national surveys from 2000 to 2010 showed a decrease in AIDS-related and an increase in non-AIDS-related deaths. Deaths notified in PLHIV followed between January 1, 2011 and December 31, 2015 in 1 of 13 participating hospitals northeast of Paris area were described. Risk factors for death were assessed, using a multivariable logistic regression model. Of 14,403 individuals, 295 died. Median age at death was 52 years (interquartile range = 47–60) and 77% were men. Sixty-seven individuals (23%) died from non-AIDS-defining nonviral hepatitis-related (NaNH) malignancy, 40 (14%) from AIDS, 34 (12%) from cardiovascular disease (CVD), 33 (11%) from non-AIDS infection, 21 (7%) from liver disease, and 12 (4%) from suicide. Men and women born in sub-Saharan Africa had a lower adjusted odds ratio (aOR) of dying than men having sex with men (MSM) born in France (0.70, 95% confidence interval = 0.45–1.09; and 0.45, 0.28–0.73, respectively). Risk factors for death were older age (aOR = 2.26, 1.36–3.77 for 40–49 years and 2.91, 1.75–4.84 for >50 years vs. 18–39 years), male intravenous drug users (IVDU) transmission (2.24, 1.42–3.54 vs. MSM born in France), AIDS (2.75, 2.10–3.59), antiretroviral therapy initiation in earlier periods, time since HIV diagnosis <1 year, low CD4 cell count nadir, hepatitis B virus and/or hepatitis C virus coinfection (1.69, 1.23–2.30), and psychiatric disorders (1.73, 1.27–2.38). Our study confirms the increasing frequency of non-AIDS-related deaths, mainly NaNH malignancies and CVD, in PLHIV, justifying overall and in some specific populations (psychiatric and IVDU) prevention and screening.
Get full access to this article
View all access options for this article.
References
1.
SiddiqiAE, HallHI, HuX, SonqR: Population-based estimates of life expectancy after HIV diagnosis: United States 2008–2011. J Acquir Immune Defic Syndr, 2016; 72:230–236.
2.
LewdenC, MayT, RosenthalE, et al.; ANRS EN19 Mortalité Study Group and Mortavic1: Changes in causes of death among adults infected by HIV between 2000 and 2005: The “Mortalité 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr, 2008; 48:590–598.
3.
LeoneS, GregisG, QuinzanG, et al.: Causes of death and risk factors among HIV-infected persons in the HAART era: Analysis of a large urban cohort. Infection, 2011; 39:13–20.
4.
AldazP, Moreno-IribasC, EgüésN, et al.: Mortality by causes in HIV-infected adults: Comparison with the general population. BMC Public Health, 2011; 11:300.
5.
GalliL, SpagnuoloV, SalpietroS, et al.: Mortality of HIV-infected patients with or without cancer: Comparison with the general population in Italy. Antivir Ther, 2012; 17:447–458.
6.
EffrosRB, FletcherCV, GeboK, et al.: Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions. Clin Infect Dis, 2008; 47:542–553.
7.
CostagliolaD: Demographics of HIV and aging. Curr Opin HIV AIDS, 2014; 9:294–301.
8.
LewdenC, SalmonD, MorlatP, et al.; Mortality 2000 study group: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol, 2005; 34:121–130.
9.
MorlatP, RoussillonC, HenardS, et al.; ANRS EN20 Mortalité 2010 Study Group: Causes of death among HIV-infected patients in France in 2010 (national survey): Trends since 2000. AIDS, 2014; 28:1181–1191.
10.
SilueY, Mounchetrou NjoyaI, LepoutreA: HIV/AIDS in Ile-de-France: the challenge of early diagnosis (Le VIH/SIDA en Ile-de-France: l'enjeu du dépistage précoce). Bulletin 1/2017 de l'ORS et de la CIRE Ile-de-France. Available at: http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-infectieuses/VIH-sida-IST/Infection-a-VIH-et-sida/Actualites accessed August1, 2018.
11.
PuglieseP, CuzinL, CabiéA, et al.; Nadis Group: A large French prospective cohort of HIV-infected patients: The Nadis Cohort. HIV Med, 2009; 10:504–511.
12.
CotteL, FerryT, PuglieseP, et al.; Dat'AIDS study group: Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy—Results from a large French multicenter cohort study. PLoS One, 2017; 12:e0170661.
13.
PattersonS, JoseS, SamjiH, et al.; Canadian Observational Cohort (CANOC)-UK Collaborative HIV Cohort (UK CHIC) Collaboration: A tale of two countries: All-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. HIV Med, 2017; 18:655–666.
14.
PettitAC, GigantiMJ, IngleSM, et al.; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators: Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. J Int AIDS Soc, 2018; 21. DOI: 10.1002/jia2.25031.
15.
GrabarS, LanoyE, AllavenaC, et al.; Clinical Epidemiology Group of the French Hospital Database on HIV: Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med, 2008; 9:246–256.
16.
AbgrallS, Del GiudiceP, MelicaG, CostagliolaD; FHDH-ANRS CO4: HIV-associated tuberculosis and immigration in a high-income country: Incidence trends and risk factors in recent years. AIDS, 2010; 24:763–771.
17.
HleyhelM, BelotA, BouvierAM, et al.; French Hospital Database on HIV–ANRS CO4 Cohort: Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: Results from the FHDH-ANRS CO4 cohort. Clin Infect Dis, 2013; 57:1638–1647.
18.
ThriftAP, ChiaoEY: Are non-HIV malignancies increased in the HIV-infected population?. Curr Infect Dis Rep, 2018; 20:22.
19.
HleyhelM, BelotA, BouvierAM, et al.; FHDH-ANRS CO4: Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J Cancer, 2015; 137:2443–2453.
20.
SigelK, MakinsonA, ThalerJ: Lung cancer in persons with HIV. Curr Opin HIV AIDS, 2017; 12:31–38.
21.
ChalouniM, SalmonD, ValantinM-A, et al., for the ANRS CO13 HEPAVIH study group: Mortality rates and causes of death according to inclusion period in HIV/HCV patients. XXVI Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, WA, March 2019.
22.
De MonteynardL, MatheronS, GrabarS, et al., on behalf of the FHDH-ANRS CO4: Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. PLoS One, 2018; 13:e0205385.
23.
LuzPM, BruyandM, RibeiroS, et al.; IPEC/FIOCRUZ Cohort and the Aquitaine ANRS CO3 Study Group: AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: Hospital-based cohort studies. BMC Infect Dis, 2014; 14:278.
24.
IngleSM, MayMT, GillMJ, et al.; Antiretroviral Therapy Cohort Collaboration: Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis, 2014; 59:287–297.
25.
Antiretroviral Therapy Cohort Collaboration (ART-CC): Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV, 2017; 4:e349–e356.
26.
Antiretroviral Therapy Cohort Collaboration (ART-CC): Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US. Antivir Ther, 2015; 20:21–28.
27.
Del AmoJ, JarrinI, MayM, et al.; for the Antiretroviral Therapy Collaboration (ART-CC): Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe and the United States. Clin Infect Dis, 2013; 56:1800–1809.
28.
MongeS, JarrinI, MocroftA, et al.; Migrants Working Group on behalf of COHERE in EuroCoord: Mortality in migrants living with HIV in Western Europe (1997–2013): A collaborative cohort study. Lancet HIV, 2015; 2:e540–e549.
29.
MarsicanoE, Dray-SpiraR, LertF, et al.: ANRS-Vespa2 study group. Multiple discriminations experienced by people living with HIV in France: Results from the ANRS-Vespa2 study. AIDS Care, 2014; 26:S97–S106.
30.
CroxfordS, KitchingA, DesaiS, et al.: Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: An analysis of a national observational cohort. Lancet Public Health, 2017; 2:e35–e46.
31.
AdejumoO, OladejiB, AkpaO, et al.: Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria. Int J STD AIDS, 2016; 27:938–949.
32.
HentzienM, CabieA, PuglieseP, et al.; Dat'AIDS Study Group: Factors associated with deaths from suicide in a French nationwide HIV-infected cohort. HIV Med, 2018 [Epub ahead of print]; DOI: 10.1111/hiv.12633.
